Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2024 12:00 ET | Source: Oxurion NV

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative...
April 25, 2024 13:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered...
April 15, 2024 11:16 ET | Source: Oxurion NV

Publication Annual Report – Annual Shareholders' Meeting

Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has...
April 15, 2024 07:00 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
April 11, 2024 13:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Leuven, BELGIUM – April 11, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
April 10, 2024 13:00 ET | Source: Oxurion NV

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels:...
April 05, 2024 08:00 ET | Source: Oxurion NV

Postponement Annual Shareholders Meeting - Amendment financial calendar

Postponement Annual Shareholders Meeting - Amendment financial calendarLeuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in...
March 28, 2024 14:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 28, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
March 27, 2024 14:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion...
March 26, 2024 14:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR...